Program
aflutinib
Also written as “Furmonertinib”, “Alflutinib” and “ASK120067”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Neoplasm Metastasis · Breast Neoplasms, led by 6 companies.
Drug pageAflutinib: every studyMany companies study it; this page follows only the 21 they lead. All 63 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Allist Pharmaceuticalsits history only | 114 open or running | phase 3since Apr 12, 2021 | Nov 21, 2016 | Dec 2026phase 3 · NCT04853342 |
| Beijing Aosaikang Pharmaceuticalits history only | 41 open or running | phase 3since Oct 12, 2019 | Apr 10, 2018 | none ahead |
| ArriVent BioPharmaits history only | 33 open or running | phase 3since Oct 31, 2022 | Apr 6, 2022 | Feb 2029phase 3 · NCT07185997 |
| Abbisko Caymanits history only | 11 open or running | phase 2since Oct 30, 2024 | Oct 30, 2024 | Dec 30, 2027phase 2 · NCT06668103 |
| Alphamab Oncology | 11 open or running | phase 1since Mar 5, 2025 | Mar 5, 2025 | Jun 30, 2028phase 1 · NCT06868732 |
| MediLink Therapeutics (Suzhou)its history only | 11 open or running | phase 2since Sep 3, 2025 | Sep 3, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Alphamab Oncology only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 5, 2025First study: phase 1 study in Advanced Non-small Cell Lung CancerFirst studyNCT06868732 · 288 planned · China
Ahead
- Jun 30, 2028Primary completion: phase 1 study in Advanced Non-small Cell Lung CancerNCT06868732
TargetBeta
“The mesylate salt form of alflutinib, an orally available selective inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, ”NCIt, by rule
Other programs on EGFR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 55 |
| pimurutamab | Fosun Pharma | phase 3 | 17 |
| Anti-EGFR Antibody-drug Conjugate CPO301 | CSPC Pharmaceutical Group | phase 3 | 16 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| becotatug | CSPC Pharmaceutical Group | phase 3 | 11 |
| andamertinibrule | avistone-biotechnology-co-ltd | phase 3 | 10 |
| becotatug vedotinrule | lepu-biopharma-co-ltd | phase 3 | 10 |
| sevabertinibrule | Bayer | phase 3 | 8 |
| HS-10504 | Hansoh Pharmaceutical Group | phase 3 | 7 |
| petosemtamabrule | Genmab | phase 3 | 6 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| zipalertinibrule | Otsuka | phase 3 | 4 |
Studies
The one study Alphamab Oncology leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06868732Advanced Non-small Cell Lung Cancer · China | 1 | Recruiting | Jun 30, 2028 | 288 |
How it is read
Names in the registry
- “Furmonertinib”, 6 entries
- “Alflutinib”, 3 entries
- “ASK120067”, 3 entries
- “Firmonertinib”, 2 entries
- “Furmonertinib 160mg”, 2 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 10 studies
- Neoplasm Metastasis, 1 study
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.